Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Quantitative prediction of human pharmacokinetics is critical in assessing the viability of drug candidates and in determining first-in-human dosing. Numerous prediction methodologies, incorporating both in vitro and preclinical in vivo data, have been developed in recent years, each with advantages and disadvantages. However, the lack of a comprehensive data set, both preclinical and clinical, has limited efforts to evaluate the optimal strategy (or strategies) that results in quantitative predictions of human pharmacokinetics. To address this issue, the authors conducted a retrospective analysis using 50 proprietary compounds for which in vitro, preclinical pharmacokinetic data and oral single-dose human pharmacokinetic data were available. Five predictive strategies, involving either allometry or use of unbound intrinsic clearance from microsomes or hepatocytes, were then compared for their ability to predict human oral clearance, half-life through predictions of systemic clearance, volume of distribution, and bioavailability. Use of a single-species scaling approach with rat, dog, or monkey was as accurate as or more accurate than using multiple-species allometry. For those compounds cleared almost exclusively by P450-mediated pathways, scaling from human liver microsomes was as predictive as single-species scaling of clearance based on data from rat, dog, or monkey. These data suggest that use of predictive methods involving either single-species in vivo data or in vitro human liver microsomes can quantitatively predict human in vivo pharmacokinetics and suggest the possibility of streamlining the predictive methodology through use of a single species or use only of human in vitro microsomal preparations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dogs, for example, lack N-acetyltransferase 2 (NAT2) activity, and rabbit cecotrophy alters enteric absorption (see Table 1 note); both confound extrapolation of oral PK [6,18,26].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [18]
In the citing paper
“Using multiple species to build the composite normalized curve improves robustness, and the quality of the human prediction depends primarily on the accuracy of the CL and Vss predictions [18,63].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [18]
In the citing paper
“More generally, drugs cleared predominantly by glomerular filtration or by physiological processes conserved across mammals tend to scale well; renally eliminated small molecules such as the aminoglycoside gentamicin fall into this category, and systematic comparisons confirm that simple allometry and its refinements predict human clearance most reliably for this class [18,26].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [18]
In the citing paper
“This qualification step also determines whether the panel can support a body-weight regression at all, or whether mechanism-specific or human-relevant in vitro approaches must carry the prediction [6,18,21].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [18]
In the citing paper
“PBPK verification practice has adopted the same bound, so agreement at this level reflects the practical resolution of the methods rather than genuine mechanistic identity [18,64,100,102,103].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [18]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
Brian Houston, J. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90520-7 · Cited by 925 · cited 1×
“The predictive utility of HLM scaling was consistent with previously reported findings.(3,6) However, the limitation of these in vitro systems has also been recognized,(46) and a tendency to underpredict has been reported.”
ResultThe prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
Sun, K. (2005) · Chinese New Drugs Journal · Cited by 762
Pharmacokinetic/pharmacodynamic data analysis : concepts and applications
Gabrielsson, J., & Weiner, D. (2002) · Cited by 712
Quantitative Relations in the Physiological Constitutions of Mammals
Adolph, E. F. (1949) · Science · doi:10.1126/science.109.2841.579 · Cited by 500
Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., & Sugiyama, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00184-2 · Cited by 479
Obach, R. S., Lombardo, F., & Waters, N. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020479 · Cited by 462
Dedrick, R. L. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059667 · Cited by 397
Man versus Beast: Pharmacokinetic Scaling in Mammals
Mordenti, J. (1986) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600751104 · Cited by 388
Cao, X., Gibbs, S. T., Fang, L., Miller, H. A., Landowski, C. P., Shin, H.-C., Lennernas, H., Zhong, Y., Amidon, G. L., Yu, L. X., et al. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9041-2 · Cited by 388
A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics
Jones, H. M., Parrott, N., Jorga, K., & Lav??, T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645050-00006 · Cited by 352
Self-citationBoxenbaum, H. (1980) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01065191 · Cited by 347
Banker, M. J., Clark, T. H., & Williams, J. A. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10332 · Cited by 305
Ito, K., & Houston, J. B. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9015-1 · Cited by 260
Linear Correlation of the Fraction of Oral Dose Absorbed of 64 Drugs Between Humans and Rats
Chiou, W. L., & Barve, A. (1998) · Pharmaceutical Research · doi:10.1023/a:1011981317451 · Cited by 257
Interspecies Scaling: Predicting Clearance of Drugs in Humans. Three Different Approaches
Mahmood, I., & Balian, J. D. (1996) · Xenobiotica · doi:10.3109/00498259609052491 · Cited by 257
Effect of Altered Plasma Protein Binding on Apparent Volume of Distribution
Øie, S., & Tozer, T. N. (1979) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600680948 · Cited by 256
Red Blood Cells: A Neglected Compartment in Pharmacokinetics and Pharmacodynamics
Hinderling, P. H. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01329-2 · Cited by 250
In Vitro Analysis of Human Drug Glucuronidation and Prediction of in Vivo Metabolic Clearance
Soars, M. G., Burchell, B., & Riley, R. J. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.382 · Cited by 228
Ward, K. W., & Smith, B. R. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.603 · Cited by 212
Self-citationLave, T. H., Dupin, S., Schmitt, C., Chou, R. C., Jaeck, D., & Coassolo, P. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js960440h · Cited by 184 · cited 1×
“Because species differences in CL can occur, the inclusion of a factor accounting for differences in CLint determined from in vitro microsomal metabolism systems into single-species scaling was evaluated.(5) However, inclusion of this factor did not improve the accuracy of the predictions.”
MethodThe pivotal role of hepatocytes in drug discovery
Soars, M. G., McGinnity, D. F., Grime, K., & Riley, R. J. (2007) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.11.002 · Cited by 173
Drug Metabolism and Drug Interactions: Application and Clinical Value of In Vitro Models
Venkatakrishnan, K., von Moltke, L., Obach, R., & Greenblatt, D. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489361 · Cited by 162
Lav??, T., Coassolo, P., & Reigner, B. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936030-00003 · Cited by 162
Metabolic turnover rate: A physiological meaning of the metabolic rate per unit body weight
Kleiber, M. (1975) · Journal of Theoretical Biology · doi:10.1016/0022-5193(75)90110-1 · Cited by 158
Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo
Soars, M. G., Grime, K., Sproston, J. L., Webborn, P. J. H., & Riley, R. J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.014464 · Cited by 153
Interspecies Prediction of Human Drug Clearance Based on Scaling Data from One or Two Animal Species
Tang, H., Hussain, A., Leal, M., Mayersohn, M., & Fluhler, E. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016188 · Cited by 150
A NOVEL MODEL FOR PREDICTION OF HUMAN DRUG CLEARANCE BY ALLOMETRIC SCALING
Tang, H., & Mayersohn, M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004143 · Cited by 141
Oral bioavailability and first-pass effects.
Kwan, K. C. (1997) · PubMed · Cited by 132
Paine, S. W., Parker, A. J., Gardiner, P., Webborn, P. J. H., & Riley, R. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019455 · Cited by 112
Interspecific Scaling of Toxicity Data
Travis, C. C., & White, R. K. (1988) · Risk Analysis · doi:10.1111/j.1539-6924.1988.tb01158.x · Cited by 107
Effective Half‐Life in Clinical Pharmacology
Boxenbaum, H., & Battle, M. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04117.x · Cited by 106 · cited 1×
“Half-life was calculated according to equation (3) and represents the “effective” t1/2 governing drug accumulation.(23) t1=2 = − lnð2Þ • t ln Rc−1 Rc , where t is the dosing frequency andRc=0−∞ AUC0− t .”
Ward, K. W., & Smith, B. R. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.612 · Cited by 105
Self-citationLiu, L., Cui, Y., Chung, A. Y., Shitara, Y., Sugiyama, Y., KEPPLER, D. O. R., & Pang, K. S. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103390 · Cited by 103
Cui, D., Booth-Genthe, C. L., Carlini, E., Carr, B., & Schrag, M. L. (2004) · PubMed · doi:10.1124/dmd.32.11 · Cited by 98
Nagilla, R., & Ward, K. W. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20169 · Cited by 96
Chang, C. K., Pang, K. S., Swaan, P. W., & Ekins, S. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.082370 · Cited by 94
Scaling basic toxicokinetic parameters from rat to man.
Bachmann, K., Pardoe, D., & White, D. (1996) · Environmental Health Perspectives · doi:10.1289/ehp.96104400 · Cited by 90
Tang, H., & Mayersohn, M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20481 · Cited by 89 · cited 1×
“Recent reports also indicate that allometry can lead to large vertical allometry errors in clearance, which can be reduced by incorporating protein binding differences between rat and human.(35,39,40) The analysis described herein demonstrated that single-species scaling of unbound clearance provides predictions with…”
BackgroundLam, J. L., & Benet, L. Z. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.11.1311 · Cited by 85
Lam, J. L., Okochi, H., Huang, Y., & Benet, L. Z. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009258 · Cited by 79
Fagerholm, U. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.6.0007 · Cited by 76
Chiou, W. L., Robbie, G. J., Chung, S. M., Wu, T., & Ma, C. (1998) · Pharmaceutical Research · doi:10.1023/a:1011974226596 · Cited by 61
Tahara, H., Kusuhara, H., Chida, M., Fuse, E., & Sugiyama, Y. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.094052 · Cited by 54
Similarity in the linear and non-linear oral absorption of drugs between human and rat
Chiou, W. L., Ma, C., Chung, S. M., Wu, T. C., & Jeong, H. Y. (2000) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp38532 · Cited by 50
Kinetics of Partitioning and Binding of Digoxin and Its Analogues in the Subcompartments of Blood
Hinderling, P. H. (1984) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600730807 · Cited by 33
Chiou, W. L., & Hsu, F.-H. (1988) · Pharmaceutical Research · doi:10.1023/a:1015935206569 · Cited by 28
Sawada, Y., Sugiyama, Y., Miyamoto, Y., Iga, T., & Hanano, M. (1985) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.33.319 · Cited by 24
Literature growth in pharmacokinetics
Boxenbaum, H. G. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059265 · Cited by 17
Tang, H., & Mayersohn, M. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016444 · Cited by 16
Tang, H., & Mayersohn, M. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005285457 · Cited by 15
Basis for body weight exponent (0.75) as a scaling factor in energy metabolism and risk assessment
Sidhu, K. S. (1992) · Journal of Applied Toxicology · doi:10.1002/jat.2550120503 · Cited by 14
Dosage Intervals Based on Mean Residence times
Wagner, J. G. (1987) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600760111 · Cited by 9
Cited by
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Central nervous system multiparameter optimization desirability: Application in drug discovery
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00029 · Cited by 653
Coexistence of passive and carrier-mediated processes in drug transport
Sugano, K., Kansy, M., Artursson, P., Avdeef, A., Bendels, S., Di, L., Ecker, G. F., Faller, B., Fischer, H., Gerebtzoff, G., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3187 · Cited by 649
Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., & Will, Y. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100007x · Cited by 477
Stepan, A. F., Subramanyam, C., Efremov, I. V., Dutra, J. K., O’Sullivan, T. J., DiRico, K. J., McDonald, W. S., Won, A., Dorff, P. H., Nolan, C. E., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300094u · Cited by 468
Metadata
- Authors
- Hosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., & Beaumont, K.
- Affiliations
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Novartis (United States) (US)
- Taisho Pharmaceutical (Japan) (JP)
- Corresponding author
- Hosea, Natilie A.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2009-05
- Volume
- 49
- Issue
- 5
- Pages
- 513-533
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2027179985
- Cited by
- 300
- References
- 53
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 9 · 2023: 12 · 2022: 15 · 2021: 9 · 2020: 18 · 2019: 17 · 2018: 17 · 2017: 20 · 2016: 17 · 2015: 17 · 2014: 16 · 2013: 19 · 2012: 26
- FWCI
- 28.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- human pharmacokinetic prediction, allometric scaling, human liver microsomes, hepatocytes, oral clearance, half-life, volume of distribution, bioavailability, first-in-human dosing
- MeSH terms
- Administration, Oral, Animals, Biological Availability, Biometry, Drug Evaluation, Preclinical, Half-Life, Humans, Metabolic Clearance Rate, Microsomes, Liver, Models, Biological, Pharmacokinetics, Retrospective Studies, Species Specificity, Reproducibility of Results, Xenobiotics, Area Under Curve, Hepatocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.